NasdaqGS:MBXPharmaceuticals
Assessing MBX Biosciences (MBX) Valuation After CEO Share Purchase And Phase 3 Hypoparathyroidism Plans
MBX Biosciences (MBX) is back on investor radars after CEO P. Kent Hawryluk reported buying 18,500 additional shares as the company prepares its lead hypoparathyroidism therapy for a Phase 3 trial.
See our latest analysis for MBX Biosciences.
At a latest share price of $28.50, MBX has seen a 1 year total shareholder return of about 2.7x, while its 30 day share price return of 12.4% and year to date share price return of 6.7% suggest some recent cooling in momentum after a strong run into...